

Edwin S Bremer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2550477/publications.pdf>

Version: 2024-02-01

71
papers

2,635
citations

147801

31
h-index

197818

49
g-index

72
all docs

72
docs citations

72
times ranked

3612
citing authors

#	ARTICLE	IF	CITATIONS
1	The multifaceted role of autophagy in cancer and the microenvironment. <i>Medicinal Research Reviews</i> , 2019, 39, 517-560.	10.5	146
2	The Role of Macrophages in Cancer Development and Therapy. <i>Cancers</i> , 2021, 13, 1946.	3.7	143
3	Targeted induction of apoptosis for cancer therapy: current progress and prospects. <i>Trends in Molecular Medicine</i> , 2006, 12, 382-393.	6.7	123
4	Therapeutic potential of Galectin-9 in human disease. <i>Medicinal Research Reviews</i> , 2013, 33, E102-26.	10.5	120
5	Mechanisms of Translocation of ER Chaperones to the Cell Surface and Immunomodulatory Roles in Cancer and Autoimmunity. <i>Frontiers in Oncology</i> , 2015, 5, 7.	2.8	117
6	Simultaneous Inhibition of Epidermal Growth Factor Receptor (EGFR) Signaling and Enhanced Activation of Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Receptor-mediated Apoptosis Induction by an scFv:sTRAIL Fusion Protein with Specificity for Human EGFR. <i>Journal of Biological Chemistry</i> , 2005, 280, 10025-10033.	3.4	88
7	Low-Dose Metformin Reprograms the Tumor Immune Microenvironment in Human Esophageal Cancer: Results of a Phase II Clinical Trial. <i>Clinical Cancer Research</i> , 2020, 26, 4921-4932.	7.0	86
8	Target cell-restricted and -enhanced apoptosis induction by a scFv:sTRAIL fusion protein with specificity for the pancarcinoma-associated antigen EGP2. <i>International Journal of Cancer</i> , 2004, 109, 281-290.	5.1	85
9	Target Cell-Restricted Apoptosis Induction of Acute Leukemic T Cells by a Recombinant Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Fusion Protein with Specificity for Human CD7. <i>Cancer Research</i> , 2005, 65, 3380-3388.	0.9	83
10	Carbon monoxide-Releasing Molecule-2 (CORM-2) attenuates acute hepatic ischemia reperfusion injury in rats. <i>BMC Gastroenterology</i> , 2010, 10, 42.	2.0	80
11	Selective induction of apoptosis in leukemic B-lymphoid cells by a CD19-specific TRAIL fusion protein. <i>Cancer Immunology, Immunotherapy</i> , 2008, 57, 233-246.	4.2	73
12	Targeting of the Tumor Necrosis Factor Receptor Superfamily for Cancer Immunotherapy. <i>ISRN Oncology</i> , 2013, 2013, 1-25.	2.1	65
13	Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivo. <i>Molecular Cancer</i> , 2010, 9, 301.	19.2	58
14	CD20-selective inhibition of CD47-SIRP α signaling with a bispecific antibody-derivative enhances the anticancer activity of daratumumab, alemtuzumab and obinutuzumab. <i>Oncolimmunology</i> , 2018, 7, e1386361.	4.6	58
15	A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability. <i>Leukemia</i> , 2009, 23, 1389-1397.	7.2	57
16	Frequency of Th17 CD20+ cells in the peripheral blood of rheumatoid arthritis patients is higher compared to healthy subjects. <i>Arthritis Research and Therapy</i> , 2011, 13, R208.	3.5	56
17	Calreticulin, a therapeutic target?. <i>Expert Opinion on Therapeutic Targets</i> , 2016, 20, 1137-1147.	3.4	56
18	Review: On TRAIL for malignant glioma therapy?. <i>Neuropathology and Applied Neurobiology</i> , 2010, 36, 168-182.	3.2	54

#	ARTICLE	IF	CITATIONS
19	CD7-restricted activation of Fas-mediated apoptosis: a novel therapeutic approach for acute T-cell leukemia. <i>Blood</i> , 2006, 107, 2863-2870.	1.4	53
20	Exceptionally Potent Anti-Tumor Bystander Activity of an scFv:sTRAIL Fusion Protein with Specificity for EGP2 Toward Target Antigen-Negative Tumor Cells. <i>Neoplasia</i> , 2004, 6, 636-645.	5.3	49
21	CD20+inflammatory T-cells are present in blood and brain of multiple sclerosis patients and can be selectively targeted for apoptotic elimination. <i>Multiple Sclerosis and Related Disorders</i> , 2014, 3, 650-658.	2.0	49
22	The epithelial polarity regulator LGALS9/galectin-9 induces fatal frustrated autophagy in KRAS mutant colon carcinoma that depends on elevated basal autophagic flux. <i>Autophagy</i> , 2015, 11, 1373-1388.	9.1	49
23	Superior Activity of Fusion Protein scFvRit:sFasL over Cotreatment with Rituximab and Fas Agonists. <i>Cancer Research</i> , 2008, 68, 597-604.	0.9	47
24	The histone deacetylase inhibitor valproic acid potently augments gemtuzumab ozogamicin-induced apoptosis in acute myeloid leukemic cells. <i>Leukemia</i> , 2007, 21, 248-252.	7.2	46
25	Antibody-based fusion proteins to target death receptors in cancer. <i>Cancer Letters</i> , 2013, 332, 175-183.	7.2	46
26	Galectin-9 Activates and Expands Human T-Helper 1 Cells. <i>PLoS ONE</i> , 2013, 8, e65616.	2.5	43
27	A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint. <i>Oncolmunology</i> , 2018, 7, e1466016.	4.6	42
28	Targeted delivery of a designed sTRAIL mutant results in superior apoptotic activity towards EGFR-positive tumor cells. <i>Journal of Molecular Medicine</i> , 2008, 86, 909-924.	3.9	37
29	The Ever-Expanding Immunomodulatory Role of Calreticulin in Cancer Immunity. <i>Frontiers in Oncology</i> , 2015, 5, 35.	2.8	36
30	The Glycan-Binding Protein Galectin-9 Has Direct Apoptotic Activity toward Melanoma Cells. <i>Journal of Investigative Dermatology</i> , 2012, 132, 2302-2305.	0.7	35
31	Programmed Death Ligand 1 (PD-L1)-targeted TRAIL combines PD-L1-mediated checkpoint inhibition with TRAIL-mediated apoptosis induction. <i>Oncolmunology</i> , 2016, 5, e1202390.	4.6	35
32	Cell Surface Delivery of TRAIL Strongly Augments the Tumoricidal Activity of T Cells. <i>Clinical Cancer Research</i> , 2011, 17, 5626-5637.	7.0	32
33	Elevated serum CXCL16 is an independent predictor of poor survival in ovarian cancer and may reflect pro-metastatic ADAM protease activity. <i>British Journal of Cancer</i> , 2014, 110, 1535-1544.	6.4	30
34	Potent Systemic Anticancer Activity of Adenovirally Expressed EGFR-Selective TRAIL Fusion Protein. <i>Molecular Therapy</i> , 2008, 16, 1919-1926.	8.2	29
35	Galectin-9 Is a Possible Promoter of Immunopathology in Rheumatoid Arthritis by Activation of Peptidyl Arginine Deiminase 4 (PAD-4) in Granulocytes. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4046.	4.1	28
36	CD47 Expression Defines Efficacy of Rituximab with CHOP in Non-Germinal Center B-cell (Non-GCB) Diffuse Large B-cell Lymphoma Patients (DLBCL), but Not in GCB DLBCL. <i>Cancer Immunology Research</i> , 2019, 7, 1663-1671.	3.4	28

#	ARTICLE	IF	CITATIONS
37	Cancer cell-expressed SLAMF7 is not required for CD47-mediated phagocytosis. <i>Nature Communications</i> , 2019, 10, 533.	12.8	26
38	C-type lectin-like molecule-1 (CLL1)-targeted TRAIL augments the tumoricidal activity of granulocytes and potentiates therapeutic antibody-dependent cell-mediated cytotoxicity. <i>MAbs</i> , 2015, 7, 321-330.	5.2	22
39	The Biophysical Interaction of the Danger-Associated Molecular Pattern (DAMP) Calreticulin with the Pattern-Associated Molecular Pattern (PAMP) Lipopolysaccharide. <i>International Journal of Molecular Sciences</i> , 2019, 20, 408.	4.1	22
40	EpCAM in morphogenesis. <i>Frontiers in Bioscience - Landmark</i> , 2008, Volume, 5050.	3.0	21
41	Targeted delivery of CD40L promotes restricted activation of antigen-presenting cells and induction of cancer cell death. <i>Molecular Cancer</i> , 2014, 13, 85.	19.2	21
42	The Neutrophil: The Underdog That Packs a Punch in the Fight against Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7820.	4.1	21
43	Bispecific Antibody Approach for Improved Melanoma-Selective PD-L1 Immune Checkpoint Blockade. <i>Journal of Investigative Dermatology</i> , 2019, 139, 2343-2351.e3.	0.7	20
44	Melanoma-Directed Activation of Apoptosis Using a Bispecific Antibody Directed at MCSP and TRAIL Receptor-2/Death Receptor-5. <i>Journal of Investigative Dermatology</i> , 2016, 136, 541-544.	0.7	18
45	CD20 ⁺ T cells have a predominantly Tc1 effector memory phenotype and are expanded in the ascites of patients with ovarian cancer. <i>Oncology</i> , 2015, 4, e999536.	4.6	17
46	Inhibition of Autophagy Does Not Re-Sensitize Acute Myeloid Leukemia Cells Resistant to Cytarabine. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2337.	4.1	16
47	CD24 Is a Potential Immunotherapeutic Target for Mantle Cell Lymphoma. <i>Biomedicines</i> , 2022, 10, 1175.	3.2	16
48	Selective elimination of pathogenic synovial fluid T-cells from Rheumatoid Arthritis and Juvenile Idiopathic Arthritis by targeted activation of Fas-apoptotic signaling. <i>Immunology Letters</i> , 2011, 138, 161-168.	2.5	15
49	A CD47-blocking TRAIL fusion protein with dual pro-phagocytic and pro-apoptotic anticancer activity. <i>British Journal of Haematology</i> , 2014, 164, 304-307.	2.5	15
50	DSP107 combines inhibition of CD47/SIRP α axis with activation of 4-1BB to trigger anticancer immunity. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 97.	8.6	12
51	CD20 positive CD8 T cells are a unique and transcriptionally-distinct subset of T cells with distinct transmigration properties. <i>Scientific Reports</i> , 2021, 11, 20499.	3.3	11
52	Galectin-9 Triggers Neutrophil-Mediated Anticancer Immunity. <i>Biomedicines</i> , 2022, 10, 66.	3.2	11
53	Direct and Indirect Rituximab-Induced T Cell Depletion: Comment on the Article by M \ddot{a} let et al. <i>Arthritis and Rheumatology</i> , 2014, 66, 1053-1053.	5.6	10
54	Endoplasmic reticulum stress-induced release and binding of calreticulin from human ovarian cancer cells. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1655-1669.	4.2	10

#	ARTICLE	IF	CITATIONS
55	Targeted elimination of activated hepatic stellate cells by an anti-epidermal growth factor receptor single chain fragment variable antibody-tumor necrosis factor-related apoptosis-inducing ligand (scFv425-sTRAIL). <i>Journal of Gene Medicine</i> , 2014, 16, 281-290.	2.8	8
56	CD40- and 41BB-specific antibody fusion proteins with PDL1 blockade-restricted agonism. <i>Theranostics</i> , 2022, 12, 1486-1499.	10.0	8
57	High Loading Efficiency and Controlled Release of Bioactive Immunotherapeutic Proteins Using Vaterite Nanoparticles. <i>Particle and Particle Systems Characterization</i> , 2021, 38, 2100012.	2.3	7
58	Abstract A076: DSP107—a novel SIRP-4-1BBL dual signaling protein (DSP) for cancer immunotherapy. <i>Cancer Immunology Research</i> , 2019, 7, A076-A076.	3.4	7
59	Towards Immunotherapy-Induced Normalization of the Tumor Microenvironment. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, .	3.7	7
60	A versatile pretargeting approach for tumour-selective delivery and activation of TNF superfamily members. <i>Scientific Reports</i> , 2017, 7, 13301.	3.3	6
61	Whispering Gallery Modes-based biosensors for real-time monitoring and binding characterization of antibody-based cancer immunotherapeutics. <i>Sensors and Actuators B: Chemical</i> , 2021, 346, 130512.	7.8	6
62	Development of Bispecific Antibody Derivatives for Cancer Immunotherapy. <i>Methods in Molecular Biology</i> , 2019, 1884, 335-347.	0.9	5
63	Expression of CD39 Identifies Activated Intratumoral CD8+ T Cells in Mismatch Repair Deficient Endometrial Cancer. <i>Cancers</i> , 2022, 14, 1924.	3.7	5
64	EpCAM-targeted induction of apoptosis. <i>Frontiers in Bioscience - Landmark</i> , 2008, Volume, 5042.	3.0	3
65	A Better TRAIL Variant for Tumor Cell-Specific Targeting? Letter. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 2853-2853.	4.1	3
66	Editorial: Endoplasmic Reticulum and Its Role in Tumor Immunity. <i>Frontiers in Oncology</i> , 2015, 5, 252.	2.8	1
67	CD47, a multi-faceted target for cancer immunotherapy. <i>Atlas of Genetics and Cytogenetics in Oncology and Haematology</i> , 2017, , .	0.1	1
68	Apoptosis Induction for Cancer Therapy. , 2011, , 242-244.		1
69	Bifunctional Antibody Fragment-Based Fusion Proteins for the Targeted Elimination of Pathogenic T-Cell Subsets. <i>Methods in Molecular Biology</i> , 2014, 1134, 79-93.	0.9	1
70	Antibody-based targeting of TNF-ligands for cancer therapy. <i>European Journal of Molecular and Clinical Medicine</i> , 2017, 2, 67.	0.1	0
71	Apoptosis Induction for Cancer Therapy. , 2015, , 328-330.		0